We inferred that one of the main reasons for inhibiting tumor proliferation was that the deficiency of ABHD17C caused less infiltration of MDSCs and was also accompanied by changes in the immune microenvironment combined with anti-PD1 therapy. This evidence concerns the gene PDCD1 and neoplasm.